Sponsored by
They reported median survival of 20 months for recurrent glioblastoma. 84% alive 1 year after starting treatment. This is unheard of and is a breakthrough in brain tumor treatments. It was a single arm trial so no randomized controls, but we would expect 8-9 months. It is approved in Japan, but we can not get it in the USA. I tried asking the company to open a trial or expanded access here and they do not want to yet, because of our regulatory system. We need to change this now.